ClinicalTrials.Veeva

Menu

Protein, Sarcopenic Obesity, and COPD (PROSO-COPD)

U

University of Aberdeen

Status

Not yet enrolling

Conditions

Chronic Obstructive Pulmonary Diseases
Sarcopenic Obesity

Treatments

Other: the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes

Study type

Observational

Funder types

Other

Identifiers

NCT06735573
T Baabbad
University of Aberdeen

Details and patient eligibility

About

Both sarcopenic obesity and chronic obstructive pulmonary diseases (COPD) are common conditions that mainly affect middle-aged and older adults. Previous research has shown that increased dietary intake of total and plant-based protein is associated with a lower risk of sarcopenic obesity, using data from the EPIC Norfolk study. Furthermore, a systematic review and meta-analysis showed that having sarcopenic obesity was associated with significantly impaired lung function outcomes. Other research has shown that increased intake of dietary protein leads to a better treatment outcome for respiratory diseases. The aim of this pilot observational study is to investigate, in more detail, the relationship between the quantity and source of dietary protein intake, the prevalence of sarcopenic obesity, and lung function, in a small cohort of older female participants with COPD. The study will also consider the role of inflammation in relation to sarcopenic obesity and lung function outcomes. This study will help to improve the understanding of the relationship between sarcopenic obesity and lung function outcomes, and how dietary protein intake and inflammation can affect this relationship and each of the outcomes.

Enrollment

30 estimated patients

Sex

Female

Ages

55+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Women.
  • Clinically diagnosed with COPD.
  • Aged 55 years or older.

Exclusion criteria

  • Male.
  • Women who are 54 years or younger.
  • Those who have dementia.
  • Unable to read or write in English.
  • Unable to attend the Human Intervention Studies Unit.
  • Those within one year life expectancy.
  • Those who have cancer.

Trial contacts and locations

0

Loading...

Central trial contact

Tasneem A Baabbad, PhD student; Baukje de Roos, MSc,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems